Indivior PLC (NASDAQ:INDV) Short Interest Update

by · The Cerbat Gem

Indivior PLC (NASDAQ:INDV – Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 2,060,000 shares, a growth of 68.9% from the February 13th total of 1,220,000 shares. Currently, 1.9% of the company’s stock are short sold. Based on an average daily volume of 1,440,000 shares, the days-to-cover ratio is currently 1.4 days.

Analyst Upgrades and Downgrades

INDV has been the topic of several recent analyst reports. RODMAN&RENSHAW raised Indivior to a “strong-buy” rating in a research report on Tuesday, January 28th. Piper Sandler lowered their price target on Indivior from $16.00 to $13.00 and set an “overweight” rating on the stock in a research report on Thursday, March 6th. Finally, Rodman & Renshaw initiated coverage on Indivior in a research report on Tuesday, January 28th. They set a “buy” rating and a $16.00 price target on the stock.

Read Our Latest Stock Report on INDV

Indivior Stock Up 0.9 %

Shares of NASDAQ:INDV traded up $0.09 during trading on Friday, reaching $9.68. 856,224 shares of the company traded hands, compared to its average volume of 609,270. The company’s 50 day moving average is $10.64 and its two-hundred day moving average is $10.50. The firm has a market capitalization of $1.33 billion, a PE ratio of -27.66 and a beta of 0.82. Indivior has a 52 week low of $7.33 and a 52 week high of $22.53.

Indivior (NASDAQ:INDV – Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The company reported $0.32 earnings per share for the quarter, hitting the consensus estimate of $0.32. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. The business had revenue of $298.00 million during the quarter, compared to the consensus estimate of $262.35 million. As a group, research analysts anticipate that Indivior will post 1.22 EPS for the current year.

Institutional Trading of Indivior

Several institutional investors and hedge funds have recently modified their holdings of INDV. GF Fund Management CO. LTD. bought a new stake in shares of Indivior during the 4th quarter worth $36,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Indivior during the 4th quarter worth $56,000. Lazard Asset Management LLC acquired a new position in Indivior in the 4th quarter worth about $57,000. Stifel Financial Corp acquired a new position in Indivior in the 3rd quarter worth about $100,000. Finally, Melqart Asset Management UK Ltd acquired a new position in Indivior in the 3rd quarter worth about $132,000. 60.33% of the stock is currently owned by institutional investors.

About Indivior

(Get Free Report)

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

See Also